Edwards Lifesciences LLC v. Cook Inc.

582 F.3d 1322, 92 U.S.P.Q. 2d (BNA) 1599, 2009 U.S. App. LEXIS 20906, 2009 WL 2998543
CourtCourt of Appeals for the Federal Circuit
DecidedSeptember 22, 2009
Docket2009-1006
StatusPublished
Cited by90 cases

This text of 582 F.3d 1322 (Edwards Lifesciences LLC v. Cook Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Edwards Lifesciences LLC v. Cook Inc., 582 F.3d 1322, 92 U.S.P.Q. 2d (BNA) 1599, 2009 U.S. App. LEXIS 20906, 2009 WL 2998543 (Fed. Cir. 2009).

Opinion

LOURIE, Circuit Judge.

Edwards Lifesciences LLC and Endogad Research PTY Limited (collectively, “Edwards”) appeal from the judgment of the United States District Court for the Northern District of California granting summary judgment of noninfringement of several claims of U.S. Patents 6,582,458 (“the '458 patent”); 6,613,073 (“the '073 patent”); 6,685,736 (“the '736 patent”); and 6,689,158 (“the '158 patent”). See Edwards Lifesciences LLC v. Cook, No. C 03-03817 JSW, 2007 WL 2128333, 2007 U.S. Dist. Lexis 55634 (N.D.Cal. July 23, 2007) (“Claim Construction Order”); Edwards Lifesciences LLC v. Cook, No. C 03-03817 JSW, 2008 WL 744825, 2008 U.S. Dist. Lexis 21248 (N.D.Cal. Mar. 18, 2008) (“Order Granting Cook Summary Judgment ”); Edwards Lifesciences LLC v. Cook, No. C 03-03817 JSW, 2008 WL 4279666, 2008 U.S. Dist. Lexis 70130 (N.D.Cal. Sept. 15, 2008) (“Order Granting Gore Summary Judgment ”). Because the court correctly construed certain claim terms and correctly determined that Cook Incorporated’s and W.L. Gore & Associates, Inc.’s (collectively, “Appellees’ ”) devices did not infringe under those constructions, we affirm.

BACKGROUND

Edwards owns the four patents in suit, which are related and share a common specification. 1 The patents relate to intraluminal grafts for treating aneurisms and occlusive diseases of the blood vessels without open surgery. See '458 patent col.l 11.11-20. An aneurism is a weakness *1325 in a blood vessel, such as the aorta, that can cause enlargement or dilation of the vessel. If an aneurism is not repaired, the vessel can rupture, resulting in serious injury or death. To avoid the adverse consequences of open surgery, the medical profession has developed techniques for repairing aneurisms endovascularly, or intraluminally, allowing surgeons to make a small incision and guide a specially made device through the arteries to the aneurism. In endovascular aneurism repair, a graft reinforced with a metal framework, also called a stent-graft, is compressed onto a delivery catheter, which is guided through the artery to the aneurism site. Once at the site, the graft is expanded into position against the walls of the blood vessel. Stents, and therefore stent-grafts, are generally classified into two types, self-expanding and balloon expandable. A self-expanding stent or stent-graft is inserted into a blood vessel inside a catheter. Upon release from the catheter, it automatically expands to the size of the vessel. See id. at col.l 11.20-31. A balloon expandable stent or stent-graft, on the other hand, is guided through a catheter on an inflatable balloon until it extends from the catheter into the vessel. See id. at eol.l 11.54-63. At that point, the balloon is inflated, expanding the stent or stent-graft to the size of the vessel, and then the balloon is deflated and removed. See id.

The specification describes one method of treating an aneurism using two overlapping grafts, whereby the degree of overlap can be adjusted to change the overall length of the graft. '458 patent col.4 11.4— 17. The specification also describes a “trouser graft,” which has a bifurcation at its downstream end, and a supplemental graft that overlaps with one of the legs of the trouser graft. Id. at col.4 11.18-31.

In August 2003, Edwards sued Cook for infringement of claims 1-3, 6, 8, 9, 11, 12, 15, and 17-20 of the '458 patent; claims 1-3, 6, 8, 9, 12, and 14-19 of the '073 patent; claims 1-á, 6, 9, 10, 12, 14-20, and 22-25 of the '736 patent; and claims 1, 15, 17, and 18-23 of the '158 patent. Edwards sued Gore for infringement of claims 1-3, 7, 8, 11, 12, and 16-20 of the '458 patent; claims 1-3, 7-9, 13-15, and 17-19 of the '073 patent; claims 1-3, 7-9, 12-15, and 22-25 of the '736 patent; and claims 1, 2, 4-6, 8, 11-14, and 17-22 of the '158 patent. Claim 1 of the '458 patent is representative of the asserted claims:

1. A prosthesis comprising:
(i) a bifurcated base structure which defines a common flow lumen and a pair of connector legs which define divergent flow lumens from the common flow lumen; and
(ii) a graft which is adapted to be anchored within one of the flow lumens of said bifurcated base structure to form a continuous extension of that lumen.

'458 patent col.6 11.12-19. All of the asserted independent claims recite two of the following structures (in addition to any recitations in the preambles): a “graft” (’458 patent claim 1), a “graft body” (’073 patent claim 1; '736 patent claims 1, 20, 22), a “graft structure” (’158 patent claims 1, 15, 17, 23), a “bifurcated base structure” (’458 patent claim 1), and a “bifurcated base graft structure” (’158 patent claims 1, 15, 17, 23). Further, in all of the asserted independent claims, those two structures are “anchored” (’458 patent claim 1; '158 patent claim 1), “attached” (T58 patent claims 15, 17, 23), “attachable” (’736 patent claims 1, 20, 22), or “dockable” (’073 patent claim 1) to each other while they are inside the vessel. 2

*1326 In July 2007, the district court construed certain limitations of the asserted claims. The court construed the claim term “graft” to mean “an intraluminal device that is used in unitary fashion to substitute, repair, or replace a missing or defective part of a vessel.” Claim Construction Order, 2007 WL 2128333, at *8, 2007 U.S. Dist. Lexis 55634, at *26. The court reasoned that the graft had to be intraluminal because the specification used the term “graft” as shorthand for “intraluminal graft” and referred to an “intraluminal graft” as “the invention.” Id. at *7, 2007 U.S. Dist. Lexis 55634, at *19-22. The court further reasoned that the claimed “graft” could not encompass a traditional surgically implanted vascular graft because all of the disclosed embodiments contained wires, which the parties agreed are a feature of intraluminal grafts. Id. at *8, 2007 U.S. Dist. Lexis 55634, at *22-26. According to the court, the claimed “graft” could not include a traditional vascular graft also because the claims required that the “graft” components be used together in a unitary fashion, preventing the device from being comprised, in part, of a device that had already been implanted. Id.

The court construed the term “graft body” to mean “an artificial device formed of plastic or fabric for use inside of a vessel.” Claim Construction Order, 2007 WL 2128333, at *12, 2007 U.S. Dist. Lexis 55634, at *37. The court reasoned that the graft body did not include malleable wires because, throughout the specification, the inventors distinguished between the material of the graft body and the wires. Id. at *13, 2007 U.S. Dist. Lexis, at *35-37.

The court construed the terms “bifurcated base structure” and “bifurcated base graft structure” to mean “an intraluminal graft that has one opening at its upstream end and two openings at its downstream end and which includes at least one malleable wire.” Claim Construction Order,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
582 F.3d 1322, 92 U.S.P.Q. 2d (BNA) 1599, 2009 U.S. App. LEXIS 20906, 2009 WL 2998543, Counsel Stack Legal Research, https://law.counselstack.com/opinion/edwards-lifesciences-llc-v-cook-inc-cafc-2009.